Ewing sarcoma is an aggressive cancer of bone and soft tissue in children with poor prognosis. It is characterized by the chromosomal translocation between EWS and an Ets family transcription factor, most commonly FLI-1. EWS-FLI-1 fusion accounts for 85% of Ewing sarcoma cases.
Introduction
Ewing sarcoma is an aggressive cancer of bone and soft tissue in children with poor longterm outcome. Ewing sarcoma is characterized by the reciprocal chromosomal translocation generating a fusion oncogene between EWS and an Ets family transcription factor, most commonly FLI-1 [1] [2] [3] [4] [5] . EWS-FLI-1 translocation accounts for 85% of Ewing sarcoma cases. The EWS-FLI-1 gene product regulates the expression of a number of genes important for cancer progression [6] , can transform mouse cells such as NIH3T3 [7] and C3H10T1/2 [8] , and is necessary for proliferation and tumorigenicity of Ewing sarcoma cells [1] [2] [3] [4] [5] . These findings suggest that EWS-FLI-1 plays a central role in Ewing sarcomagenesis although the role for the reciprocal fusion, FLI-1-EWS, was also suggested recently [9] .
IGF signaling plays an important role in Ewing sarcomagenesis. IGF-1 and IGF-1R expression are elevated in Ewing sarcoma cell lines and tumors [10, 11] . Blockage of IGF-1R by a monoclonal antibody inhibits the xenograft tumorigenicity of Ewing sarcoma cells [12] . IGF-1R expression is necessary for transformation of mouse fibroblasts by EWS-FLI-1 [13] .
Expression of EWS-FLI-1 in mesenchymal stem cells, the putative cells of origin for Ewing sarcoma [1] [2] [3] [4] [5] , results in the induction of IGF-1 and IGF-1 dependence for cell growth [14, 15] .
EWS-FLI-1 directly represses the expression of IGFBP3 [16] , which functions as an inhibitor of IGF signaling by binding and sequestering IGFs.
Using secretome proteomics, we found that EWS-FLI-1 induces the expression of pappalysin-1, a cell surface protease that cleaves IGFBP2, IGFBP4, and IGFBP5 [17, 18] . Like IGFBP3, IGFBP2, IGFBP4, and IGFBP5 function as inhibitors of IGF signaling. We demonstrate that EWS-FLI-1 binds to the gene promoter of pappalysin-1 and activates its expression. Silencing of pappalysin-1 resulted in accumulation of IGFBPs and reduced bioactive P a g e | 4
IGF-1 in Ewing sarcoma cell secretome, leading to suppression of IGF signaling. Pappalysin-1 silencing strongly inhibited both anchorage-dependent and anchorage-independent growth as well as xenograft tumorigenicity of Ewing sarcoma cells. These results suggest the critical role played by the EWS-FLI-1pappalysin-1 axis in creating a cell surface microenvironment that facilitates IGF signaling in Ewing sarcoma. P a g e | 5
Results & Discussion

EWS-FLI-1 activates pappalysin-1 expression in Ewing sarcoma.
To dissect the impact of EWS-FLI-1 on Ewing sarcoma cell secretome, we silenced EWS-FLI-1 using lentiviruses expressing an shRNA against FLI-1 C-terminal region in A673 Ewing sarcoma cells ( Fig. 1A ; luciferase shRNA as control) and analyzed the proteins secreted in the conditioned medium by GeLC-MS/MS and spectral counting. (The details of the proteomic analysis will be published elsewhere.) From this, we found dramatically reduced pappalysin-1 protein levels in A673 cell secretome upon EWS-FLI-1 silencing ( Fig. 1B ). EWS-FLI-1 silencing also reduced pappalysin-1 transcript levels in A673 cells (Fig. 1C ). Conversely, exogenous expression of EWS-FLI-1 in human mesenchymal stem cells, the putative cells of origin of Ewing sarcoma [1] [2] [3] [4] [5] , induced pappalysin-1 transcript levels ( Fig. 1D ). Using chromatin immunoprecipitation, we detected the binding of EWS-FLI-1 to the papplysin-1 gene promoter in A673 and EW8 Ewing sarcoma cells, and this binding was abolished by shRNAmediated silencing of EWS-FLI-1 (Fig. 2) . These results indicate that papplysin-1 is a novel direct transcriptional target of EWS-FLI-1. Consistent with the activation of pappalysin-1 gene transcription by EWS-FLI-1, Ewing sarcoma tumors and cell lines expressed high levels of pappalysin-1 mRNA compared with mesenchymal stem cells ( Fig. 3 ).
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Silencing of pappalysin-1 results in accumulation of IGFBPs, reduced bioactive IGF-1, and reduced IGF signaling in Ewing sarcoma.
Pappalysin-1 is a cell surface metalloproteinase that cleaves IGFBP2, IGFBP4, and IGFBP5 and releases IGF from inhibitory IGFBPs, leading to increased local bioavailability of IGF and enhanced IGF signaling [17, 18] . As shown in Fig. 4 , silencing of pappalysin-1 by siRNA resulted in the accumulation of IGFBP2, IGFBP4, and IGFBP5 in the secretome of four Ewing sarcoma cell lines (A673, EW8, TC32, and TC71). Free bioactive IGF-1 levels dramatically declined in A673 and EW8 cell secretome upon papplysin-1 silencing ( Fig. 5 ), which is consistent with the accumulation of IGFBPs ( Fig. 4 ). Tyrosine auto-phosphorylation of IGF-1 receptor and serine 473 phosphorylation of Akt were significantly reduced upon pappalysin-1 silencing in all four Ewing sarcoma cell lines ( Fig. 4) . These results suggest that the proteolytic cleavage of IGFBPs by pappalysin-1 is necessary for the maintenance of IGF signaling in Ewing sarcoma.
Silencing of pappalysin-1 inhibits anchorage-dependent and anchorage-independent growth and xenograft tumorigenicity of Ewing sarcoma cells.
Pappalysin-1 silencing by siRNA or shRNA ( Fig 6A) strongly inhibited the proliferation of Ewing sarcoma cells ( Fig. 6B and 6D ). Proliferation arrest induced by pappalysin-1 silencing was completely rescued by the addition of recombinant pappalysin-1 protein to the culture medium ( Fig. 6C ), indicating that Ewing sarcoma is dependent on extracellular pappalysin-1 protein.
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One of the hallmarks of cancer is the ability to proliferate independent of anchorage.
Importantly, silencing of pappalysin-1 in A673 cells resulted in dramatic inhibition of soft agar colony formation ( Fig. 6E ), indicating that pappalysin-1 plays an essential role in anchorageindependent growth of Ewing sarcoma cells.
To test the role of pappalysin-1 in the tumorigenicity of Ewing sarcoma, we employed xenograft tumorigenicity assays in SCID mice. A673 cells were infected with lentiviruses expressing two different shRNAs against pappalysin-1 or control scrambled shRNA. After puromycin selection, cells were subcutaneously injected into the flanks of SCID mice. Tumor volume was determined using a caliper. As shown in Fig. 6F , pappalysin-1 silencing strongly inhibited xenograft tumor growth (p < 0.05).
Collectively, these results indicate that pappalysin-1 is required for in vitro and in vivo growth of Ewing sarcoma cells.
It is well established that IGF signaling plays an important role in Ewing sarcoma. High levels of IGF-1 and IGF-1R are expressed in Ewing sarcoma cell lines and tumors [10, 11] and inhibition of IGF-1R suppresses the xenograft tumorigenicity of Ewing sarcoma cells [12] .
EWS-FLI-1 was shown to silence the expression of IGFBP3, an inhibitor of IGF signaling [16] .
In this study, we uncovered that EWS-FLI-1 creates a cell surface microenvironment that is conducive to IGF signaling through direct transcriptional induction of pappalysin-1, a cell surface protease that cleaves IGFBP2, IGFBP4, and IGFBP5 (concept shown in Fig. 7 ). Our data suggest that pappalysin-1 stimulates IGF signaling in Ewing sarcoma by increasing the bioactive IGF levels in the vicinity of cell surface where IGF and IGF-1R interaction occurs.
Downregulation of pappalysin-1 dramatically inhibited anchorage-dependent and anchorage-P a g e | 8
independent growth and xenograft tumorigenicity of Ewing sarcoma cells. These results indicate that despite high IGF-1 and IGF-1R expression and silencing of IGFBP3 by EWS-FLI-1, Ewing sarcoma is additionally dependent on pappalysin-1 to sustain IGF signaling and cell proliferation.
Important roles played by IGF signaling in Ewing sarcoma had generated high hopes for therapeutic targeting of this pathway, primarily by anti-IGF-1R antibodies. However, anti-IGF-1R clinical trials in Ewing sarcoma resulted in relatively low response rates [19] [20] [21] [22] [23] [24] [25] . The data presented in this paper suggest that downregulating pappalysin-1 to limit the cell surface bioavailability of IGF merits further investigation as an alternative to anti-IGF-1R antibodies.
Additionally, a recent study identified pappalysin-1 as Ewing sarcoma tumor antigen and generated CD8 + T cells engineered to express TCR specific to pappalysin-1, which displayed anti-Ewing sarcoma effect in mouse xenograft models [26] . This study indicated that pappalysin-1 is a suitable antigen for cytotoxic T cell-mediated killing of Ewing sarcoma. Our data suggest that pappalysin-1 is a functionally important target in Ewing sarcoma, in addition to being a promising antigenic target for T cell-mediated immunotherapy. Therefore, it will now be important to determine the efficacy of pappalysin-1 targeting in Ewing sarcoma, both by immunotherapy and by pharmacological inhibition of pappalysin-1 activity. P a g e | 9 
Materials & Methods
Protein sample preparation and proteomic analysis
The preparation of secreted protein samples, GeLC-MS/MS analysis, and proteomics data analysis were performed essentially as described [29] . A673 cells were infected with lentiviruses P a g e | 10
expressing an shRNA against FLI-1 C-terminal region or luciferase (control) and were selected with 2 µg/ml puromycin for 2 days. Cells were washed six times with DMEM without serum.
Subsequently, cells were cultured in DMEM without serum for 24 hours and the culture supernatant was harvested. The supernatant was centrifuged, filtered through a 0.45 μm filter (Millipore), and concentrated using a 3,000 Dalton cut-off Amicon Ultra Centrifugal Filter Units GCTGATCCCAATTCTCTTTCA; GAPDH 5' primer, GGTGTGAACCATGAGAAGTATGA, 3' primer, GAGTCCTTCCACGATACCAAAG.
Immunoblotting, ELISA, and antibodies Immunoblotting was performed as described [27, 28] . The levels of free bioactive IGF-1
were determined using IGF-I Bioactive ELISA (AnshLabs). The following antibodies were used: rabbit polyclonal anti-phospho-Akt (9271, Cell Signaling Technologies); rabbit polyclonal anti- 
Cell proliferation assays
Anchorage-dependent cell proliferation was assessed by IncuCyte live-cell imaging system and by crystal violet staining.
Anchorage-independent cell proliferation was evaluated by soft agar colony formation assays. A673 cells were infected with lentiviruses expressing shRNAs against pappalysin-1 or scrambled shRNA and were selected with 2 µg/ml puromycin. Four days after infection, 4x10 3 cells were plated in soft agar. The soft agar cultures were comprised of two layers: a base layer (4 ml in a 60 mm dish; DMEM/10% fetal calf serum/0.6% noble agar (A5431, Sigma-Aldrich)/ penicillin/streptomycin) and a cell layer (2 ml in a 60 mm dish; DMEM/10% fetal calf serum/0.3% noble agar/penicillin/streptomycin). Colonies were grown for three weeks and counted. Colonies (>50 cells) were scored by randomly counting 10 fields per dish.
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Xenograft tumorigenicity assays A673 cells were infected with lentiviruses expressing pappalysin-1 shRNAs or scrambled shRNA and were selected with 2 µg/ml puromycin for 2 days. Each cell type was subcutaneously injected into the flanks of SCID mice (2x10 6 cells/injection, n=5). Tumor growth was monitored weekly using a caliper.
Statistical analysis
Statistical significance was calculated by using Graphpad Prism software (version 6.0f) with a two-tailed Student's t test.
P a g e | 14 The binding of EWS-FLI-1 to the pappalysin-1 promoter was examined by chromatin immunoprecipitation in A673 and EW8 Ewing sarcoma cells. Two different primer pairs (#1 and #2) were used to amplify 1, 2, and 3 kb upstream regions. The specificity of the binding was verified by EWS-FLI-1 silencing. EZH2 [34] and NR0B1 [35] are known EWS-FLI-1 targets.
Figure Legends
GAPDH serves as a negative control. Pappalysin-1 was silenced in A673 and EW8 cells as in Figure 4 and the levels of free bioactive IGF-1 were determined using bioactive IGF-1 ELISA. Asterisks denote p < 0.05 compared with control siRNA transfected cells. (E) Pappalysin-1 silencing inhibits anchorage-independent growth of Ewing sarcoma cells.
A673 were infected with lentiviruses expressing shRNAs against pappalysin-1 or control scrambled shRNA and were selected with 2 µg/ml puromycin. Four days after infection, cells were plated in semi-solid medium. Three week after culture, colonies were counted and photographed. Asterisks denote p < 0.05 compared with control shRNA-expressing cells.
(E) Pappalysin-1 silencing inhibits xenograft tumorigenicity of Ewing sarcoma cells.
A673 cells were infected with lentiviruses expressing pappalysin-1 shRNAs or control scrambled shRNA and were selected with 2 µg/ml puromycin for 2 days. Each cell type was subcutaneously injected into the flanks of SCID mice (2x10 6 cells/injection, n=5). Tumor growth was monitored weekly using a caliper. The photograph of dissected tumors at 5 weeks after injection is shown on the top. 
Figure 4
Pappalysin-1 silencing results in accumulation of IGFBPs and reduced IGF signaling in Ewing sarcoma cells. Figure 5 Pappalysin-1 silencing results in reduced bioactive IGF-1 levels in Ewing sarcoma secretome. Figure 6 Pappalysin-1 silencing inhibits in vitro and in vivo growth of Ewing sarcoma cells. Figure 7 Model for the stimulation of IGF signaling by pappalysin-1 in Ewing sarcoma.
